Retention among transgender women treated with dolutegravir associated with tenofovir/lamivudine or emtricitabine in Argentina: TransViiV study

In Argentina, transgender women (TGW) have a high HIV prevalence (34%). However, this population shows lower levels of adherence, retention in HIV care and viral suppression than cisgender patients. The World Health Organization (WHO) recommends the transition to dolutegravir (DTG)-based regimens to...

Descripción completa

Detalles Bibliográficos
Autores principales: Frola, Claudia E., Aristegui, Inés, Figueroa, María I., Radusky, Pablo D., Cardozo, Nadir, Zalazar, Virginia, Cesar, Carina, Patterson, Patricia, Fink, Valeria, Gun, Ana, Cahn, Pedro, Sued, Omar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9858466/
https://www.ncbi.nlm.nih.gov/pubmed/36662723
http://dx.doi.org/10.1371/journal.pone.0279996

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9858466/
https://www.ncbi.nlm.nih.gov/pubmed/36662723
http://dx.doi.org/10.1371/journal.pone.0279996

Ejemplares similares